Evaluation of Two Different CMV-Immunoglobulin Regimens for Combined CMV Prophylaxis in High-Risk Patients following Lung Transplant.

Víctor Manuel Cuesta MoraPiedad UssettiAlicia de PabloDavid Fernández IturbeRosalía LaportaRodrigo AlonsoMyriam AguilarCarlos A QuezadaJosé M Cifrián

Published in: Microorganisms (2022)

Extending the adjunctive CMV-Ig prophylaxis beyond the manufacturer's recommendations up to one year does not confer additional clinical benefits regarding lung post-transplantation outcomes.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
stem cells
metabolic syndrome
clinical practice
patient reported outcomes